Founded in 1974, Sanguine Corp. is a company focused on pioneering the development and commercialization of innovative perfluorocarbon-based therapies and medical devices. The Company’s lead product is PHER-02. This intravenous perfluorocarbon emulsion is highly efficient at dissolving and delivering oxygen to tissues. These properties make PHER-02 an ideal product for the treatment of an array of medical conditions with high morbidity and/or mortality directly resulting from a lack of oxygen at the cellular level. Sanguine’s shares trade on the OTC Bulletin Board and the Company has their corporate headquarters in Roswell, Georgia.
PHER-O2 is a reformulated version of Fluosol-DA. The Company plans to speed up the development of PHER-02 via strategic and targeted joint ventures, partnerships, and licenses with industry partners. PHER-O2 contains perfluorodecalin, purified water, and an emulsifier that allows the product to undergo administration intravenously. Perfluorodecalin is a biologically inert substance that is not metabolized by the body; it is excreted from the body through normal respiration. Perfluorocarbons currently have approval for use in the United States in eye surgery and medical imaging. Outside of the United States, they have approval for other medical indications.
Dr. Thomas C. Drees, MBA, PH.D. is the Founder & Chairman of Sanguine. He worked at the forefront of the blood substitute business for more than thirty years. Dr. Drees was the President and CEO of Alpha Therapeutics, the only company to obtain FDA approval for a blood substitute product for human use. The aforementioned Fluosol-DA was developed under the management of Dr. Drees. Fluosol-DA is the only FDA-approved intravenous perfluorocarbon emulsion. Sanguine believes that PHER-02 will benefit from the success of Fluosol-DA and enable the Company to pursue a fast track through the development and FDA approval process.
Sanguine’s philosophy is to develop products that have a sound scientific basis and that have demonstrated Proof of Concept. The Company’s commitment is to adhere to the highest industry standards of product development. They achieve their objectives through the employment of organic methodologies, and with strategic alliances through carefully managed partnerships with well-positioned companies, universities, research institutions, and government agencies.
The diverse medical applications of PHER-02 would include transportation of pancreas islets for treatment of diabetes; ophthalmic retinal surgery; angioplasty; external oxygenation of infection, ischemic tissue, and diabetic ulcers. Medical applications would also include Alzheimer’s disease; traumatic brain injury; oxygenation of cancerous tumors; nuclear magnetic resonance imaging; CAT scans; cardioplegia or the priming of heart-lung machines in open-heart surgery; and treatment of heart attacks, strokes, head and neck tumors, and hemorrhagic shock.
Let us hear your thoughts below:
